The Valens Company Announces Results Of Annual And Special Meeting Of Shareholders and Change to Board of Directors

Kelowna, B.C., May 26, 2021The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF) (the “Company,” “The Valens Company” or “Valens”), a leading manufacturer of cannabis products, today announced the voting results from its Annual and Special Meeting of Shareholders (the “Meeting”), held by way of live audio webcast on May 25, 2021, in addition to a change to its Board of Directors (“Board”).

The total number of common shares of the Company (“Common Shares”) represented by shareholders present during the live audio webcast and by proxy at the Meeting was 44,391,588 Common Shares, representing 27.85% of the total issued and outstanding Common Shares as of the record date.

All of the matters put forward before shareholders for consideration and approval as set out in Valens’ notice of meeting and management information circular, dated April 19, 2021, were approved by the shareholders. In particular, shareholders approved the election of all director nominees to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Results of the vote for the election of directors at the Meeting are set out as follows:

 

Nominee Votes For % Votes Withheld %
Deepak Anand 44,304,305 99.80 87,283 0.20
Guy Beaudin 44,308,657 99.81 82,931 0.19
Andrew Cockwell 44,282,359 99.75 109,229 0.25
Karin A. McCaskill 43,410,318 97.79 981,270 2.21
Ashley McGrath 37,745,711 85.03 6,645,877 14.97
Tyler Robson 44,313,140 99.82 78,448 0.18
Drew Wolff 44,315,107 99.83 76,481 0.17

 

Full details of the foregoing and results of the Meeting are contained in the Report of Voting Results for the Meeting which is filed under Valens’ profile on SEDAR at www.sedar.com.

The Company also announced that following his re-election, Independent Director Deepak Anand advised Valens that he had to step down from the Board for personal reasons, effective immediately.

Tyler Robson, Chief Executive Officer, Co-Founder and Chair of The Valens Company, said: “Since joining Valens’ Board, Deepak has been instrumental to the growth and success of our business in Canada and globally with his strong industry knowledge and belief in our corporate vision. On behalf of Valens’ Management team and Board, I would like to sincerely thank Deepak for his impactful contributions and wish him all the best in his future endeavors.”

Robson continued: “I would also like to formally welcome Guy Beaudin and Drew Wolff to Valens’ Board, whose combined expertise and guidance will undoubtedly strengthen our corporate governance and further our ability to continue to execute on our aggressive growth plans.”

The Board Nominating and Corporate Governance Committee will continue to consider new independent Board nominations as candidates are presented.

About The Valens Company

The Valens Company is a leading manufacturer of cannabis products with a mission to bring the benefits of cannabis to the world. The Company provides proprietary cannabis processing services across five core technologies, in addition to best-in-class product development, formulation and manufacturing of cannabis consumer packaged goods. The Valens Company’s high-quality products are exclusively formulated for the medical, therapeutic, health and wellness, and recreational consumer segments, and are offered across numerous product formats, including oils, vapes, concentrates, edibles and topicals, as well as pre-rolls, with a focus on next-generation product development and innovation. Its breakthrough patented emulsification technology, SōRSE™ by Valens, converts cannabis oil into water-soluble emulsions for seamless integration into a variety of product formats, allowing for near-perfect dosing, stability, and taste. In partnership with brand houses, consumer packaged goods companies and licensed cannabis producers around the globe, the Company continues to grow its diverse product portfolio in alignment with evolving cannabis consumer preferences in key markets. Through its wholly owned subsidiary Valens Labs Ltd., the Company is setting the standard in cannabis testing and research and development with Canada’s only ISO17025 accredited analytical services lab, named The Centre of Excellence in Plant-Based Science by partner and scientific world leader Thermo Fisher Scientific. Discover more on The Valens Company and its subsidiaries at http://www.thevalenscompany.com.

For further information, please contact:

Jeff Fallows
The Valens Company

Investor Relations
ir@thevalenscompany.com
1 647.956.8254

KCSA Strategic Communications
Phil Carlson / Elizabeth Barker
VLNS@kcsa.com
1 212.896.1233 / 1 212.896.1203

Media
KCSA Strategic Communications
Anne Donohoe
adonohoe@kcsa.com
1 212.896.1265

Notice regarding Forward Looking Statements

All information included in this press release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management’s expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management’s current expectations and plans relating to the future. Wherever possible, words such as “plans”, “expects”, “scheduled”, “trends”, “indications”, “potential”, “estimates”, “predicts”, “anticipate”, “to establish”, “believe”, “intend”, “ability to”, or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will”, or are “likely” to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, all disclosure regarding future results of operations, economic conditions and anticipated courses of action.

The risks and uncertainties that may affect forward-looking statements include, among others, regulatory risk, United States border crossing and travel bans, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, reliance on a single facility, limited operating history, vulnerability to rising energy costs, unfavourable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company’s latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company’s website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management’s current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.

← Back to Press Releases